Connect with us

Hi, what are you looking for?


Cramer dubs Lilly’s Alzheimer’s drug a ‘holy grail’ after today’s data

Eli Lilly and Co (NYSE: LLY) is in focus this morning after the pharmaceutical behemoth said its “donanemab” significantly slowed progression of Alzheimer’s disease in a clinical trial.

How effective is Lilly’s drug for Alzheimer’s

The study that spanned over eighteen months confirmed that a monthly dose of the said antibody infusion helped slow memory decline by 35%.  

More importantly, those on treatment were 39% less likely to advance into the next stage of Alzheimer’s. According to Maria Carrillo – the Chief Scientific Officer of Alzheimer’s Association:

These are the strongest phase 3 data for an Alzheimer’s treatment to date.

Lilly now plans on applying for FDA approval before the end of this quarter, as per the press release. Its previous attempt to get expedited approval for donanemab was rejected due to insufficient data.

Jim Cramer reacts to the clinical trial data

Over 50% of the patients enrolled in the clinical trial completed the treatment within twelve months.

Donanemab was also shown to slow the decline in patients’ ability to perform daily activities by 40% at eighteen months. Reacting to the news on CNBC’s “Squawk Box”, famed investor Jim Cramer said:

This is far better than what Biogen has. There are some side effects that I think they can deal with. Few people have the side effects. It’s the holy grail. It’s what Eli Lilly was looking for.

Reported side effects include brain swelling and bleeding that resulted in three deaths during the trial. The pharmaceutical stock is up roughly 7.0% on Wednesday.

The post Cramer dubs Lilly’s Alzheimer’s drug a ‘holy grail’ after today’s data appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    Rep. Jennifer Wexton (D-Va.) announced on Tuesday that she has been diagnosed with Parkinson’s Disease. “If there’s one thing that Democrats and Republicans can...

    Latest News

    After Dianne Feinstein announced she’d contracted the shingles in early March, her staff said she planned to return to the Senate within a matter...


    A U.S. District Court judge has ruled that Elizabeth Holmes, founder and CEO of the disgraced blood-testing company Theranos, cannot remain free on bail...

    Latest News

    SEOUL, South Korea — When a group of American lawmakers arrived in South Korea for meetings with government and military officials, President Yoon Suk-yeol...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.